Sprint Bioscience AB (FRA:5JA1) Cyclically Adjusted Book per Share: €0.15 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:5JA1 Sprint Bioscience AB FRA:5JA1
32 GF Score
Price €0.30
GF Value €0.19
! 1 Warning Sign
View Full Analysis

What is Sprint Bioscience AB Cyclically Adjusted Book per Share?

Sprint Bioscience AB FRA:5JA1 -3.54% 32 Cyclically Adjusted Book per Share is €0.15 as of Mar. 2026. GuruFocus rates FRA:5JA1 with a GF Score™ of 32/100 and a GF Value™ of €0.19. The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Sprint Bioscience AB's adjusted book value per share for the three months ended in Mar. 2026 was €0.094. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €0.15 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Sprint Bioscience AB's average Cyclically Adjusted Book Growth Rate was -5.10% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -3.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Sprint Bioscience AB was -3.70% per year. The lowest was -3.70% per year. And the median was -3.70% per year.

As of today (2026-07-22), Sprint Bioscience AB's current stock price is €0.30. Sprint Bioscience AB's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was €0.15. Sprint Bioscience AB's Cyclically Adjusted PB Ratio of today is 2.00.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Sprint Bioscience AB was 2.37. The lowest was 0.21. And the median was 0.59.


Sprint Bioscience AB  (FRA:5JA1) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Sprint Bioscience AB's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=0.30/0.15
=2.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Sprint Bioscience AB was 2.37. The lowest was 0.21. And the median was 0.59.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Sprint Bioscience AB Cyclically Adjusted Book per Share Related Terms


Sprint Bioscience AB Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Sprint Bioscience AB's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sprint Bioscience AB Cyclically Adjusted Book per Share Chart

Sprint Bioscience AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.11 0.16 0.17 0.15

Sprint Bioscience AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.14 0.12 0.10 0.15 0.15

FRA:5JA1 vs VRTX, REGN, ALNY: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Sprint Bioscience AB's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sprint Bioscience AB Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sprint Bioscience AB's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Sprint Bioscience AB's Cyclically Adjusted PB Ratio falls into.


FRA:5JA1
32GF Score
Sprint Bioscience AB FRA:5JA1
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sprint Bioscience AB Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Sprint Bioscience AB's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.094/133.5600*133.5600
=0.094

Current CPI (Mar. 2026) = 133.5600.

Sprint Bioscience AB Quarterly Data

Book Value per Share CPI Adj_Book
201606 0.295 101.019 0.390
201609 0.272 101.138 0.359
201612 0.305 102.022 0.399
201703 0.322 102.022 0.422
201706 0.303 102.752 0.394
201709 0.359 103.279 0.464
201712 0.274 103.793 0.353
201803 0.646 103.962 0.830
201806 0.403 104.875 0.513
201809 0.334 105.679 0.422
201812 -0.011 105.912 -0.014
201903 0.327 105.886 0.412
201906 0.350 106.742 0.438
201909 0.306 107.214 0.381
201912 0.062 107.766 0.077
202003 0.007 106.563 0.009
202006 0.203 107.498 0.252
202009 0.085 107.635 0.105
202012 0.034 108.296 0.042
202103 -0.016 108.360 -0.020
202106 0.035 108.928 0.043
202109 0.177 110.338 0.214
202112 0.144 112.486 0.171
202203 0.112 114.825 0.130
202206 0.076 118.384 0.086
202209 0.049 122.296 0.054
202212 0.036 126.365 0.038
202303 0.020 127.042 0.021
202306 0.005 129.407 0.005
202309 0.039 130.224 0.040
202312 0.035 131.912 0.035
202403 0.031 132.205 0.031
202406 0.023 132.716 0.023
202409 0.017 132.304 0.017
202412 0.011 132.987 0.011
202503 0.005 132.825 0.005
202506 0.012 133.699 0.012
202509 0.005 133.480 0.005
202512 0.104 133.390 0.104
202603 0.094 133.560 0.094

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €0.15 mean?
Sprint Bioscience AB (FRA:5JA1) has a Cyclically Adjusted Book per Share of €0.15 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Sprint Bioscience AB and its competitors.
Is Sprint Bioscience AB's Cyclically Adjusted Book per Share too high?
Sprint Bioscience AB's current Cyclically Adjusted Book per Share is €0.15. Overall, Sprint Bioscience AB has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Sprint Bioscience AB's Cyclically Adjusted Book per Share compare to VRTX and REGN?
Sprint Bioscience AB's Cyclically Adjusted Book per Share of €0.15 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Sprint Bioscience AB and its competitors. Sprint Bioscience AB's current Cyclically Adjusted Book per Share is €0.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sprint Bioscience AB stock overvalued right now?
Sprint Bioscience AB (FRA:5JA1) has a current Cyclically Adjusted Book per Share of €0.15. The stock's GF Value™ is €0.19, compared to a current price of €0.30 — trading 57.9% above its estimated fair value. The current Cyclically Adjusted Book per Share is €0.15. Sprint Bioscience AB's overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Sprint Bioscience AB (FRA:5JA1), the current Cyclically Adjusted Book per Share is €0.15 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sprint Bioscience AB (FRA:5JA1) Overvalued in 2026?

Based on GuruFocus' analysis, Sprint Bioscience AB stock appears to be overvalued. The current stock price of €0.30 is trading 57.9% above its estimated GF Value™ of €0.19.

Key valuation signals for FRA:5JA1:

  • Cyclically Adjusted Book per Share: €0.15
  • GF Value™: €0.19 vs. price of €0.30 (57.9% above fair value)
  • GF Score™: 32/100 with 1 warning sign

No single metric tells the full story. See the FRA:5JA1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sprint Bioscience AB Business Description

Other Exchanges SPRINT:Sweden
Address Halsovagen 7, floor 8, elevator A, Novum, Huddinge, SWE, 141 57
Sprint Bioscience AB is a pharmaceutical company focused on developing drug candidates that can contribute to new treatments for cancer. Its product portfolio includes VRK1, VPS34, PETRA01, TREX1, NNMT, STK25, and DCPS. The company receives revenue for out-licensing drug programs, which include the development of a drug candidate.
32GF Score

Get the complete analysis for FRA:5JA1

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.30
Price
€0.19
GF Value